1 Introduction
From 2005, ovarian cancer (OC) has become the second main gynecological cause of cancer-related deaths in China, replacing uterine cancer [
1]. According to the GLOBOCAN Global Cancer Statistics, the number of new OC cases in China was 313,959, with a related mortality rate of 2.1% (207,252 patients) in 2020 [
2]. It is expected that the incidence of OC in China will continue to rise during the next decade to a higher rate than that predicted globally [
3]. In particular, advanced OC has a recurrence rate as high as 80%, with resistance to chemotherapy being a limiting factor for the success rates of relapsed OC treatments [
4].
Maintenance treatment (MT) with poly (ADP-ribose) polymerase (PARP) inhibitors is a novel option for patients with OC who had previously received platinum-based chemotherapy treatment to decrease the rates of recurrence or relapse [
5,
6]. Recently, trials and real-world studies found that olaparib with and without bevacizumab was an effective and safe MT for patients with OC [
7‐
12].
Niraparib is a potent selective PARP-1/2 inhibitor with excellent bioavailability when administered orally and is up to 100 times more active against these enzymes than other PARP family members [
13]. It was approved in the EU and USA in 2017 [
14,
15], and in China in 2019 [
16] for MT of recurrent OC. However, in several clinical trials, which analyzed outcomes of niraparib for patients with advanced OC (NOVA, QUADRA, PRIMA, NORA, and PRIME), treatment-emergent adverse events (TEAEs) were reported in 99% of the patients with 51–74% being grade ≥ 3 [
17]. It is noteworthy that niraparib increased the progression-free survival (PFS) times significantly compared with placebo [
18‐
21] as well as eliciting clinically relevant activity in heavily pretreated OC patients [
22] irrespective of their homologous recombination deficiency (HRD) status [
23]. In addition, the dosage of niraparib as an individualized starting dose (ISD) was determined by the patient’s baseline bodyweight and platelet count. If a patient’s platelet count was < 150,000/μL or their bodyweight was < 77 kg, they received a daily dose of 200 mg. For other patients, the daily dose was 300 mg. Considering that the majority of Chinese patients have a bodyweight < 77 kg, we were particularly interested in the present study to investigate whether it was more beneficial for Chinese patients to have treatment initiated at 200 mg/day compared with 100 mg/day. We also aimed to determine whether reducing the dosage of niraparib from 200 to 100 mg, following ISD dosing principles, affected treatment efficacy [
24].
To the best of our knowledge, after niraparib was covered by Chinese health insurance from 2021, multicenter studies on Chinese real-world experience with niraparib as first-line MT for OC have not been thoroughly investigated. The present large-scale observational study used real-world data to assess the efficacy and safety profile of niraparib as first-line MT in patients with newly diagnosed advanced OC, to investigate the clinical benefits associated with prolonged niraparib treatment, and to evaluate the relationship between different doses of niraparib and PFS of patients who were given a reduced dosage due to the occurrence of TEAEs.
2 Methods
2.1 Patients
Patients with advanced OC treated with niraparib as first-line MT in 15 Chinese hospitals between January 2019 and December 2021 were retrospectively enrolled in the study.
2.1.1 Inclusion Criteria
The inclusion criteria for the study were: patients ≥ 18 years old diagnosed with histologically confirmed OC [Federation International of Gynecology and Obstetrics (FIGO) stage II–IV], had underwent surgery and received first-line chemotherapy, and patients being treated with niraparib as first-line MT. Patients who exhibited disease progression or died during the follow-ups were also eligible, i.e., from the date of commencing niraparib MT to the last follow-up or death.
2.1.2 Exclusion Criteria
The exclusion criteria were: patients who had other malignancies ≤ 5 years before the study, were enrolled in previous clinical trials, and had been diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
2.2 Study Design
This multicenter observational retrospective study collected the data from comprehensive medical records of patients with advanced OC, who were treated with niraparib as first-line MT. The patients enrolled came from 15 hospitals across China, with at least 10 patients per hospital. In clinical practice, these patients received different oral doses of niraparib until disease progression, severe toxicity, or death occurred. The study was conducted from January 2019 to December 2021 (the index date was the date of initiating MT with niraparib) and the database was locked on 31 December 2022.
2.3 Study Endpoints
The primary endpoint was PFS, defined as the time from when a patient first received MT with niraparib to the date of disease progression. Clinical and objective radiology assessments were carried out according to Response Evaluation Criteria in Solid Tumors (RECIST ver. 1.1) guidelines. The secondary endpoints were the time to discontinuation (TTD) of therapy, which was defined as the time from the date of initiation of MT with niraparib to TTD and safety, which were assessed according to the incidence of TEAEs, laboratory test findings, vital signs, and physical examinations. TEAEs were graded following Common Terminology Criteria for Adverse Events (CTCAE) guidelines (ver. 5).
For exploratory outcomes, patients were stratified according to: their age when given the first dose (< 65 years versus ≥ 65 years), international FIGO stage II–IV, Eastern Cooperative Oncology Group (ECOG) performance status (0–2), chronic disease (yes versus no), breast cancer (BRCA) genes mutational status [mutated (BRCAm), wild type (BRCAwt), or unknown], HRD status (positive, negative, or unknown), CA-125 elimination rate constant K (KELIM) score (> 1, ≤ 1, or unknown), postoperative status of cytoreductive surgery (R0, R1), best response to first-line chemotherapy [complete response (CR) versus partial response (PR), or if there were any stabilizations], starting dose (100 mg, 200 mg, or 300 mg), after 3 months (100 mg, 200 mg, or 300 mg), neoadjuvant chemotherapy (yes versus no), BMI standards for Chinese people (≤ 24 kg/m2 or > 24 kg/m2), and the interval (≤ 12 weeks versus > 12 weeks) between completion of first-line chemotherapy and the start of niraparib MT.
2.4 Data Collection
Data from the medical records of all participating patients were collected from the hospital information system, including demographics, clinicopathological features, degree of residual disease after primary surgery, genetic-testing results, and other relevant information. Any missing data were obtained by telephone follow-ups or direct patient interviews (if they were alive and coherent). The rate of occurrence of TEAEs, dose reductions, dose interruptions, and discontinuation of treatment because of unacceptable TEAEs were also carefully documented. All criteria for efficacy and safety assessments were sent to the participating hospitals using uniform criteria.
2.5 Ethical Considerations
The study was conducted strictly following the guiding principles of the Declaration of Helsinki, the International Conference on Harmonization of Good Clinical Practice and appropriate legal guidelines for non-interventional and observational studies. As the study was retrospective in nature and data collection anonymized, the informed consent of patients was not required. The study was approved by the Ethics Committee of Zhongda Hospital, School of Medicine, Southeast University on 9 September 2022 (no: 2022040092). This study was registered with ClinicalTrials.gov (registration number: NCT05734911).
2.6 Statistical Analysis
Statistical analyses were carried out using R software (ver. 4.2.2). Categorical variables are reported as frequencies or a percentage, and continuous variables as the median plus range. No sample size calculation was made because of the exploratory nature of the study. The Kaplan–Meier method and the log-rank test were used for analysis of survival. The 95% confidence intervals (95% CIs) were evaluated using the Clopper–Pearson test. Safety data were summarized with descriptive statistics (numbers and percentages).
Univariate logistic regression analysis was used to identify possible risk factors for an 18-month PFS. Variables with significance (
P < 0.05) from the univariate logistic regression analysis and those of clinical interest (e.g., the interaction of surgery and chemotherapy outcome) were analyzed using the Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression model, which minimizes the influence from multicollinearity. Following this, a novel nomogram incorporating all independent prognostic factors was developed for predicting the 18-month PFS in advanced OC patients [
25].
To assess the effectiveness of the model, a receiver operating characteristic (ROC) curve was used to evaluate the discriminative ability of the nomogram. A calibration curve was used to determine the level of consistency between predicted probabilities and the observed outcomes. Missing data were designated as unknown for both analyses and a P-value < 0.05 was deemed to be significant.
4 Discussion
Several Chinese phase 3 clinical trials have confirmed that niraparib MT for recurrent OC produced significantly prolonged PFS times compared with placebo [
18,
20]. However, compared with randomized clinical trials, real-world studies are less restrictive and have broader enrollment criteria, with the patients more relevant to clinical practice. Until the end of 2021, niraparib was not covered by Chinese medical insurance. From 2021, niraparib as second-line MT was covered by Chinese medical insurance, and then first-line MT was covered by 2022. Therefore, niraparib has not been regularly administered until healthcare reimbursement, resulting in our multicenter data patient cohort being not as large as expected. At the time of the data cut-off, 131 patients remained free of disease progression, which explains why our data maturity was 36.2% (95% CI 23.4–36.5%) and the duration of follow-up differed considerably compared with other studies resulting in a not-reached median PFS (95% CI 23.8–NE). However, in the present study, niraparib as MT for OC patients within 12 weeks of completion of first-line chemotherapy regimens produced overall PFS rates of 87.4%, 75.9%, 63.6%, 56.1%, and 51.8% at 6, 12, 18, 24, and 30 months, respectively, after initiation of treatment for the entire cohort. A similar PFS rate at 18 months of 62% for niraparib plus bevacizumab MT has been published recently [
26].
LASSO regression analysis revealed that the factors influencing prolonged PFS times included age, germline
BRCA mutation status, and cytoreductive surgery outcomes. HRD-positive patients and
BRCA mutation cases had superior PFS rates, respectively, compared with HRD-negative and
BRCAwt patients, which confirms that
BRCA status and HRD positivity are factors influencing the effectiveness of niraparib therapy in patients with advanced OC [
27]. It is noteworthy that niraparib in contrast to other PARP inhibitors (e.g. olaparib) was approved in the EU and USA for first-line MT of OC, regardless of patient HRD status [
23].
Also, the cytoreductive surgery outcome status has been described as being a major factor for PFS times when niraparib MT was used for advanced OC patients [
28]. With regard to age, previous trials found that it was not a limiting factor for PFS times of OC patients receiving niraparib MT [
29,
30], but a real-world study on olaparib MT for OC patients noted that the clinical benefit regarding median PFS times was different in older, compared with younger, patients. Selection in RCTs prefers older patients with a good performance status without other major health issues, but in real-life unselected frail older patients represent a significantly larger proportion than in the cohorts enrolled in randomized controlled trials [
31].
The initial dose given to most patients in the present study was 200 mg/day, which produced the best clinical results. After 3 months from the initiation of treatment, some patients chose to discontinue or take a reduced dose due to TEAEs or personal choice. However, an average 200 mg dose led to somewhat higher PFS rates at 18 months with even lower rates of grade 3/4 TEAEs, indicating that a standard dose of 200 mg was efficient and safe, while switching to 100 mg might be necessary, mainly for cases with distinct TEAE susceptibilities, without essentially lessening the long term efficacy of treatment as reported in the PRIME study [
20]. According to a meta-analysis of recent trials, patients taking niraparib were at a higher risk of developing nausea, fatigue, anemia, platelet count decreases, vomiting, neutrophil count decreases, headache, constipation, and insomnia of any grade, as well as at a higher risk for grade 3 or 4 fatigue [
32], all findings that are in good agreement with those of the present study. The percentages of dose reduction (23.6%) and treatment discontinuation (5.5%) in our study were lower than the 70.9% and 12.0% previously observed [
19], and 59.9% and 4% [
18] reported in other studies, but similar to the 16.7% and 5.6% in the Chinese real-world study of Ni and colleagues that used only 200 mg doses [
33]. This may be due to the low number of patients taking 300 mg in the present study.
Some limitations of the present study should be considered. First, its retrospective nonexperimental design may have increased selection bias. Second, the follow-up times were not long enough to establish long-term survival outcomes. Third, the absence of BRCA mutation and especially HRD status may have affected the interpretation of the findings to some extent and led to the exclusion of HRD status in determining a PFS correlation. Finally, due to the small sample size, we were not able to divide the dataset into the training dataset and validation dataset to test the robustness of the prediction model we have developed. As a result, the present predictive model requires a larger database and further confirmation in prospective research before its clinical application.
Declarations
Author Contributions
Minmin Z: formal analysis, investigation, writing—original draft, writing—review and editing, visualization. SQ: formal analysis, writing—original draft, writing—review and editing, visualization. XW, PM, ZJ, TZ, XX, Yanling Z, BZ, DY, Yang Z, WS, AH, Min Z, WH, Yingli Z, ZS, MJ and ML: investigation, writing—review and editing, visualization. JC and JX: formal analysis, writing—review and editing, visualization. BC: conceptualization, formal analysis, resources, writing—review and editing, visualization, supervision, project administration. Ying Z: conceptualization, investigation, resources, writing—original draft, writing—review and editing, visualization, supervision, project administration, funding acquisition. YS: conceptualization, formal analysis, resources, writing—original draft, writing—review and editing, visualization, supervision, project administration, funding acquisition. All authors approved the final submitted version of the manuscript.